Application of Jingui channel-warming decoction in preparation of medicine for treating hypoovarian reserve function

Abstract

The invention relates to the technical field of traditional Chinese medicines, in particular to application of Jingui channel-warming decoction in preparation of a medicine for treating hypoovarian reserve function. The meridian-warming decoction is prepared from fructus evodiae, radix ophiopogonis, angelica sinensis, Chinese herbaceous peony, ligusticum wallichii, ginseng, cassia twig, colla corii asini, moutan bark, ginger, liquorice and pinellia ternate, and the meridian-warming decoction can effectively inhibit the deviation level of AMH, FSH and E2 in serum and can effectively treat hypoovarian reserve function.

Description

Technical Field

[0001] This invention relates to the field of traditional Chinese medicine technology, specifically to the application of Jin Kui Wen Jing Tang in the preparation of drugs for treating decreased ovarian reserve. Background Technology

[0002] Ovarian reserve (OR) refers to the ability of follicles in the ovarian cortex to grow, develop, and form fertile oocytes, which depends on the quantity and quality of the follicles in the ovary.

[0003] Diminished ovarian reserve (DOR) currently lacks a unified standard and norm for diagnosis and treatment. It refers to a decrease in the number and / or quality of oocytes in the ovaries, leading to insufficient ovarian function and decreased fertility. This is accompanied by decreased levels of anti-Müllerian hormone (AMH), reduced antral follicle count (AFC), and elevated follicle-stimulating hormone (FSH). It can be caused by various factors, such as physiological factors (age-related DOR) and various pathological factors, including risk factors for DOR such as genetic factors (e.g., family history of Fragile X syndrome), iatrogenic factors (including a history of reproductive system surgery, chemotherapy, etc.), autoimmune factors, infectious factors, environmental factors, and psychosocial factors. Patients with DOR often experience reduced fertility, including infertility or difficulty conceiving, early or recurrent miscarriage, poor ovarian response to ovulation-inducing drugs during assisted reproductive technology, or repeated embryo implantation failure. Most patients may have regular menstruation, but they may also experience various menstrual irregularities, including changes in menstrual cycle, regularity, duration of menstruation, and amount of menstrual flow.

[0004] Age-related physiological dopamine retinopathy (DOR) has become a major factor in infertility in older women. Meanwhile, due to environmental, social, and iatrogenic factors, the prevalence of pathological DOR is also gradually increasing, posing a significant threat to the fertility of younger women. Therefore, the prevention and treatment of DOR is particularly urgent in the treatment of infertility.

[0005] The efficacy of traditional Chinese medicine (TCM) in treating DOR (Dysfunction Ovary Syndrome) is widely recognized, and recent animal studies have confirmed that TCM does indeed contain components that regulate and improve the function of the hypothalamus-pituitary-ovarian axis. TCM has unique advantages in treating this disease, effectively consolidating reproductive endocrine function, reducing the likelihood of recurrence after discontinuation of medication, and improving clinical cure rates and patient compliance.

[0006] Currently, there are few reports on the use of Wenjing Decoction in treating decreased ovarian reserve. Therefore, providing relevant research and improving the efficacy of treatment for decreased ovarian reserve are technical issues that need to be addressed. Summary of the Invention

[0007] To address the aforementioned technical problems, this invention provides the application of Jin Kui Wen Jing Tang in the preparation of drugs for treating decreased ovarian reserve.

[0008] In one aspect, this invention provides the application of Jin Kui Wen Jing Tang in the preparation of drugs for treating decreased ovarian reserve. This application can be used to treat decreased ovarian reserve of the spleen and kidney yang deficiency type.

[0009] As a preferred embodiment, the raw materials for preparing the Jin Kui Wen Jing Tang are: Evodia rutaecarpa, Ophiopogon japonicus, Angelica sinensis, Paeonia lactiflora, Ligusticum chuanxiong, Panax ginseng, Cinnamomum cassia, Colla corii asini, Paeonia suffruticosa, Zingiber officinale, Glycyrrhiza uralensis, and Pinellia ternata.

[0010] As a preferred option, the ingredients of Jin Kui Wen Jing Tang, by weight, are: 8-10 parts Evodia rutaecarpa, 8-10 parts Ophiopogon japonicus, 5-7 parts Angelica sinensis, 5-7 parts Paeonia lactiflora, 5-7 parts Ligusticum chuanxiong, 5-7 parts Panax ginseng, 5-7 parts Cinnamomum cassia, 5-7 parts Colla corii asini, 5-7 parts Paeonia suffruticosa, 5-7 parts Zingiber officinale, 5-7 parts Glycyrrhiza uralensis, and 5-7 parts Pinellia ternata.

[0011] As a preferred option, the ingredients of Jin Kui Wen Jing Tang, according to weight parts, are: 9 parts Evodia rutaecarpa, 9 parts Ophiopogon japonicus, 6 parts Angelica sinensis, 6 parts Paeonia lactiflora, 6 parts Ligusticum chuanxiong, 6 parts Panax ginseng, 6 parts Cinnamomum cassia, 6 parts Colla corii asini, 6 parts Paeonia suffruticosa, 6 parts Zingiber officinale, 6 parts Glycyrrhiza uralensis, and 6 parts Pinellia ternata.

[0012] This invention also provides related technologies for combined drug use, specifically including the application of Jin Kui Wen Jing Tang combined with fermented Chinese medicine in the preparation of drugs for treating decreased ovarian reserve.

[0013] As a preferred option, the fermented Chinese medicine product is obtained by boiling and cooling Rehmannia glutinosa, Cuscuta chinensis, Morinda officinalis, Angelica sinensis, Astragalus membranaceus and Bupleurum chinense, followed by fermentation with Lactobacillus rhamnosus CICC 23119, sterilization and filtration.

[0014] As a preferred option, the raw materials of the fermented Chinese medicine are, by weight, 3-5 parts Rehmannia glutinosa, 2.5-4 parts Cuscuta chinensis, 1.5-3 parts Morinda officinalis, 1.5-3 parts Angelica sinensis, 1-2.5 parts Astragalus membranaceus and 0.8-2 parts Bupleurum chinense.

[0015] The advantages of this invention compared to the prior art are as follows: This invention uses Evodia rutaecarpa, Ophiopogon japonicus, Angelica sinensis, Paeonia lactiflora, Ligusticum chuanxiong, Panax ginseng, Cinnamomum cassia, Colla corii asini, Paeonia suffruticosa, Zingiber officinale, Glycyrrhiza uralensis, and Pinellia ternata to prepare Wenjing Decoction, which can effectively inhibit the deviation of serum AMH, FSH, and E2 levels and can effectively treat ovarian reserve deficiency.

[0016] This invention utilizes a fermented herbal product prepared from Rehmannia glutinosa, Cuscuta chinensis, Morinda officinalis, Angelica sinensis, Astragalus membranaceus, and Bupleurum chinense, which can effectively treat decreased ovarian reserve. Furthermore, the use of a specific fermenting bacterium, Lactobacillus rhamnosus CICC 23119, during the preparation of the fermented herbal product can effectively enhance its therapeutic effect on decreased ovarian reserve.

[0017] The combined drug combination of the present invention is more effective than the single drug combination, thus proving that the combined use of the Wenjing Decoction prepared by the present invention and the fermented Chinese medicine produces a synergistic effect and significantly improves the effect of treating ovarian reserve decline.

[0018] Based on the tests conducted in this invention, it can be seen that when Jin Kui Wen Jing Tang and fermented Chinese medicine are used in combination at a weight ratio of 1:0.8-1.5, the therapeutic effect is better than other comparisons, and it can further enhance the effect of treating ovarian reserve decline. Attached Figure Description

[0019] Figure 1 AMH levels in the serum of mice in each group. Detailed Implementation

[0020] The technical solution of the present invention will be clearly and completely described below with reference to the embodiments of the present invention. Obviously, the described embodiments are only some embodiments of the present invention, and not all embodiments.

[0021] This invention provides the application of Jin Kui Wen Jing Tang in the preparation of drugs for treating decreased ovarian reserve.

[0022] In one aspect, this invention provides the application of Jin Kui Wen Jing Tang in the preparation of drugs for treating decreased ovarian reserve. This application can be used to treat decreased ovarian reserve of the spleen and kidney yang deficiency type.

[0023] As a preferred embodiment, the raw materials for preparing the Jin Kui Wen Jing Tang are: Evodia rutaecarpa, Ophiopogon japonicus, Angelica sinensis, Paeonia lactiflora, Ligusticum chuanxiong, Panax ginseng, Cinnamomum cassia, Colla corii asini, Paeonia suffruticosa, Zingiber officinale, Glycyrrhiza uralensis, and Pinellia ternata.

[0024] As a preferred option, the ingredients of Jin Kui Wen Jing Tang, by weight, are: 8-10 parts Evodia rutaecarpa, 8-10 parts Ophiopogon japonicus, 5-7 parts Angelica sinensis, 5-7 parts Paeonia lactiflora, 5-7 parts Ligusticum chuanxiong, 5-7 parts Panax ginseng, 5-7 parts Cinnamomum cassia, 5-7 parts Colla corii asini, 5-7 parts Paeonia suffruticosa, 5-7 parts Zingiber officinale, 5-7 parts Glycyrrhiza uralensis, and 5-7 parts Pinellia ternata.

[0025] As a preferred option, the ingredients of Jin Kui Wen Jing Tang, according to weight parts, are: 9 parts Evodia rutaecarpa, 9 parts Ophiopogon japonicus, 6 parts Angelica sinensis, 6 parts Paeonia lactiflora, 6 parts Ligusticum chuanxiong, 6 parts Panax ginseng, 6 parts Cinnamomum cassia, 6 parts Colla corii asini, 6 parts Paeonia suffruticosa, 6 parts Zingiber officinale, 6 parts Glycyrrhiza uralensis, and 6 parts Pinellia ternata.

[0026] As a preferred embodiment, the preparation method of Jin Kui Wen Jing Tang includes the following steps: Step 1: Take the donkey-hide gelatin, crush it, add 3-5 times the weight of the donkey-hide gelatin with water, heat and melt it to obtain the pre-treated donkey-hide gelatin, set aside; Step 2: Mix Evodia rutaecarpa, Ophiopogon japonicus, Angelica sinensis, Paeonia lactiflora, Ligusticum chuanxiong, Panax ginseng, Cinnamomum cassia, Paeonia suffruticosa, Zingiber officinale, Glycyrrhiza uralensis, and Pinellia ternata to obtain the material. Add 5-50 times the weight of water to the material, decoct, filter, and obtain the medicinal liquid. Step 3: Add the processed donkey-hide gelatin to the medicinal liquid, mix, and obtain the Wenjing Decoction.

[0027] This invention also provides related technologies for combined drug use, specifically including the application of Jin Kui Wen Jing Tang combined with fermented Chinese medicine in the preparation of drugs for treating decreased ovarian reserve.

[0028] As a preferred option, the weight ratio of Jin Kui Wen Jing Tang to fermented Chinese medicine is 1:0.8-1.5.

[0029] As a preferred option, the fermented Chinese medicine product is obtained by boiling and cooling Rehmannia glutinosa, Cuscuta chinensis, Morinda officinalis, Angelica sinensis, Astragalus membranaceus and Bupleurum chinense, followed by fermentation with Lactobacillus rhamnosus CICC 23119, sterilization and filtration.

[0030] As a preferred option, the raw materials of the fermented Chinese medicine are, by weight, 3-5 parts Rehmannia glutinosa, 2.5-4 parts Cuscuta chinensis, 1.5-3 parts Morinda officinalis, 1.5-3 parts Angelica sinensis, 1-2.5 parts Astragalus membranaceus and 0.8-2 parts Bupleurum chinense.

[0031] As a preferred option, the preparation method of the fermented Chinese medicine product includes: taking Rehmannia glutinosa, Cuscuta chinensis, Morinda officinalis, Angelica sinensis, Astragalus membranaceus and Bupleurum chinense, mixing and pulverizing them to obtain a pulverized material, adding water to boil, cooling to obtain a processed material, adding sucrose and Lactobacillus casei CICC 23119, fermenting anaerobically at 30-40℃ for 2-4 days, sterilizing, filtering, and obtaining the fermented Chinese medicine product.

[0032] As a preferred option, the weight ratio of the pulverized material to water is 10-50.

[0033] As a preferred embodiment, the sucrose concentration added to the treatment is 0.5-2% by weight. The inoculum concentration of *Lactobacillus rhamnosus* in the treatment is 5 × 10⁻⁶. 9 Up to 5×10 11 bacteria / g.

[0034] Example 1

[0035] The preparation of Wenjing Decoction is as follows.

[0036] Soup 1: Ingredients, by weight: 9 parts Evodia rutaecarpa, 9 parts Ophiopogon japonicus, 6 parts Angelica sinensis, 6 parts Paeonia lactiflora, 6 parts Ligusticum chuanxiong, 6 parts Panax ginseng, 6 parts Cinnamomum cassia, 6 parts Colla corii asini, 6 parts Paeonia suffruticosa, 6 parts Zingiber officinale, 6 parts Glycyrrhiza uralensis, and 6 parts Pinellia ternata.

[0037] Preparation method: Step 1: Take donkey-hide gelatin, crush it, add 4 times the weight of water, heat to 60℃ to melt, and obtain the pretreated donkey-hide gelatin for later use; Step 2: Mix Evodia rutaecarpa, Ophiopogon japonicus, Angelica sinensis, Paeonia lactiflora, Ligusticum chuanxiong, Panax ginseng, Cinnamomum cassia, Paeonia suffruticosa, Zingiber officinale, Glycyrrhiza uralensis, and Pinellia ternata to obtain the material. Add 12 times the weight of water to the material and decoct (after boiling, cool down to 90°C and decoct at this temperature for 0.8 hours). Then cool to 50°C and filter to obtain the medicinal liquid. Step 3: Add the processed donkey-hide gelatin to the medicinal liquid, mix, and obtain the Wenjing Decoction.

[0038] Soup 2: Ingredients, by weight: 10 parts Evodia rutaecarpa, 8 parts Ophiopogon japonicus, 6 parts Angelica sinensis, 5.5 parts Paeonia lactiflora, 6 parts Ligusticum chuanxiong, 6 parts Panax ginseng, 6 parts Cinnamomum cassia, 5 parts Colla corii asini, 5 parts Paeonia suffruticosa, 5 parts Zingiber officinale, 5 parts Glycyrrhiza uralensis, and 5 parts Pinellia ternata.

[0039] Preparation method: Step 1: Take donkey-hide gelatin, crush it, add 4 times the weight of water, heat to 60℃ to melt, and obtain the pretreated donkey-hide gelatin for later use; Step 2: Mix Evodia rutaecarpa, Ophiopogon japonicus, Angelica sinensis, Paeonia lactiflora, Ligusticum chuanxiong, Panax ginseng, Cinnamomum cassia, Paeonia suffruticosa, Zingiber officinale, Glycyrrhiza uralensis, and Pinellia ternata to obtain the material. Add 12 times the weight of water to the material and decoct (after boiling, cool down to about 92°C and decoct at this temperature for 0.85 hours). Then cool to 50°C and filter to obtain the medicinal liquid. Step 3: Add the processed donkey-hide gelatin to the medicinal liquid, mix, and obtain the Wenjing Decoction.

[0040] Example 2

[0041] The preparation of fermented Chinese medicines and formulations is as follows.

[0042] Fermented product 1: Ingredients, by weight: 4 parts Rehmannia glutinosa, 3 parts Cuscuta chinensis, 2 parts Morinda officinalis, 2 parts Angelica sinensis, 1.8 parts Astragalus membranaceus, and 1.2 parts Bupleurum chinense.

[0043] Preparation method: Take Rehmannia glutinosa (processed), Cuscuta chinensis, Morinda officinalis, Angelica sinensis, Astragalus membranaceus, and Bupleurum chinense, mix and pulverize them to obtain a powder. Add 18 times the weight of water to the powder and boil. Cool to room temperature to obtain a treated product. Add 1.8% of sucrose and Lactobacillus rhamnosus CICC 23119 (the inoculum concentration in the treated product is 6.8 × 10⁻⁶) to the treated product. 10 (100 bacteria / g), fermented at 37±1℃ for 2 days in anaerobic conditions, sterilized, filtered, and the fermented Chinese medicine product was obtained.

[0044] Fermented product 2: Ingredients, by weight: 5 parts Rehmannia glutinosa, 2.5 parts Cuscuta chinensis, 2 parts Morinda officinalis, 1.5 parts Angelica sinensis, 1 part Astragalus membranaceus, and 0.8 parts Bupleurum chinense.

[0045] Preparation method: Take Rehmannia glutinosa (processed), Cuscuta chinensis, Morinda officinalis, Angelica sinensis, Astragalus membranaceus, and Bupleurum chinense, mix and pulverize them to obtain a powder. Add 18 times the weight of water to the powder and boil. Cool to room temperature to obtain a treated product. Add 2% (by weight) of sucrose and Lactobacillus rhamnosus CICC 23119 (the inoculum concentration in the treated product is 6.0 × 10⁻⁶). 10 (100 bacteria / g), fermented at 38±1℃ for 2.5 days under anaerobic conditions, sterilized, filtered, and the fermented Chinese medicine product was obtained.

[0046] Formulation 1: Ingredients, by weight: 4 parts Rehmannia glutinosa, 3 parts Cuscuta chinensis, 2 parts Morinda officinalis, 2 parts Angelica sinensis, 1.8 parts Astragalus membranaceus, and 1.2 parts Bupleurum chinense.

[0047] Preparation method: Take Rehmannia glutinosa, Cuscuta chinensis, Morinda officinalis, Angelica sinensis, Astragalus membranaceus and Bupleurum chinense, mix and pulverize them to obtain pulverized material. Add 18 times the weight of water to the pulverized material and decoct (after boiling, cool down to about 90℃ and decoct at this temperature for 1.2 hours). Then cool to 50℃ and filter to obtain preparation 1.

[0048] Example 3

[0049] Monitoring serum AMH, FSH, and E2 levels is crucial in the diagnosis and treatment of diminished ovarian reserve (DOR). AMH, secreted by the granulosa cells of preantral and small antral follicles in the ovary, directly reflects the total number of "remaining follicles" in the ovary, i.e., ovarian reserve. A decreased AMH level indicates declining ovarian reserve and a depletion of the follicular pool, one of the most direct pieces of evidence for diagnosing DOR. FSH, secreted by the pituitary gland, stimulates follicle growth and development; it reflects the amount of "effort" the pituitary gland needs to activate the ovaries. Higher FSH levels indicate a poorer ovarian response and greater functional decline. E2 is primarily secreted by developing antral follicles and reflects the functional status of currently "active and developing" follicles.

[0050] The efficacy of the above-mentioned Wenjing Decoction, fermented Chinese medicinal materials, preparations, and combinations thereof was tested. The testing methods are as follows.

[0051] Experimental animals and equipment: C57BL / 6J mice (female, 20±2g), cyclophosphamide (CTX), the above-mentioned Wenjing Decoction, fermented Chinese medicine, preparations or combinations.

[0052] Experimental procedure: Mice from the same batch were acclimatized for 3 days and then divided into groups of 10 mice each. The drug treatments for each group were as follows: Group 1, blank group, no processing.

[0053] Group 2, the model group, received intraperitoneal injections of CTX once daily at a dose of 85 mg / kg of mouse body weight.

[0054] Group 3, the drug group, received intraperitoneal injection of CTX once a day at a dose of 85 mg / kg mouse body weight, and oral administration of 800 mg / kg mouse body weight / day of the drug, which was Tang 1.

[0055] Group 4, the drug group, received intraperitoneal injection of CTX once a day at a dose of 85 mg / kg mouse body weight, and oral administration of 800 mg / kg mouse body weight / day of the drug, which was Tang 2.

[0056] Group 5, drug group: CTX was injected intraperitoneally once a day at a dose of 85 mg / kg mouse body weight, and the drug was administered by gavage at a dose of 800 mg / kg mouse body weight / day. The drug was fermentation product 1.

[0057] Group 6, the drug group, received intraperitoneal injection of CTX once a day at a dose of 85 mg / kg mouse body weight, and oral administration of 800 mg / kg mouse body weight / day of the drug, which was fermentation product 2.

[0058] Group 7, the drug group, received intraperitoneal injection of CTX once a day at a dose of 85 mg / kg mouse body weight, and oral administration of 800 mg / kg mouse body weight / day of the drug, which was formulation 1.

[0059] Group 8: Drug group, CTX was injected intraperitoneally once a day at a dose of 85 mg / kg mouse body weight, and the drug was administered by gavage at a dose of 800 mg / kg mouse body weight / day. The drug consisted of soup 1 and fermentation product 1 in a weight ratio of 1:1.5.

[0060] Group 9: Drug group, CTX was injected intraperitoneally once a day at a dose of 85 mg / kg mouse body weight, and the drug was administered by gavage at a dose of 800 mg / kg mouse body weight / day. The drug consisted of soup 1 and fermentation product 1 in a weight ratio of 1:0.8.

[0061] Group 10: Drug group, CTX was injected intraperitoneally once a day at a dose of 85 mg / kg mouse body weight, and the drug was administered by gavage at a dose of 800 mg / kg mouse body weight / day. The drug consisted of soup 1 and fermentation product 1 in a weight ratio of 1:0.4.

[0062] Group 11: Drug group. CTX was injected intraperitoneally once a day at a dose of 85 mg / kg mouse body weight, and the drug was administered by gavage at a dose of 800 mg / kg mouse body weight / day. The drug consisted of soup 1 and fermentation product 1 in a weight ratio of 1:3.

[0063] After two weeks of continuous administration, blood samples were collected from mice 10 hours after the last administration. Serum was then used to test the levels of AMH, FSH, and E2 in the serum. The results are shown in Table 1 and [Table data would be inserted here]. Figure 1 .

[0064] Table 1: Serum AMH, FSH, and E2 levels

[0065] Based on the data in Table 1, the differences between each drug group and the model group were calculated; where the differences AMH and E2 are the values ​​of the model group minus the values ​​of the drug group, and the difference FSH is the value of the drug group minus the value of the model group. The results are shown in Table 2.

[0066] Table 2: Differences in AMH, FSH, and E2 levels between each group and the model group

[0067] Based on the test results of the model group and the blank group, it can be seen that after CTX modeling, the serum levels of AMH, FSH, and E2 in the model group mice showed a significant decreasing, increasing, and decreasing trend, respectively.

[0068] The results of tests in groups 3-4 show that the Jin Gui Wen Jing Tang formula used in this invention can effectively inhibit the deviation of serum AMH, FSH, and E2 levels from the blank group, and can effectively treat decreased ovarian reserve.

[0069] Based on tests in groups 5 and 6, it is evident that the fermented herbal product prepared by fermenting Rehmannia glutinosa, Cuscuta chinensis, Morinda officinalis, Angelica sinensis, Astragalus membranaceus, and Bupleurum chinense can effectively treat decreased ovarian reserve. Furthermore, a comparison between groups 7 and 5 shows that using the specific fermenting bacterium Lactobacillus rhamnosus CICC 23119 can effectively enhance the therapeutic effect of the fermented product on decreased ovarian reserve.

[0070] A comparison of groups 8-11 with groups 3 and 5 shows that the combined medication group is more effective than the single medication group. This proves that the combined use of the Wenjing Decoction prepared in this invention and the fermented Chinese medicine produces a synergistic effect, significantly improving the treatment effect of ovarian reserve decline.

[0071] The comparison between groups 10-11 and groups 8-9 shows that when Jin Kui Wen Jing Tang and fermented Chinese medicine are used in combination at a weight ratio of 1:0.8-1.5, the efficacy is better than other comparisons, and it can further enhance the effect of treating ovarian reserve decline.

Claims

1. Application of Jin Kui Wen Jing Tang in the preparation of drugs for treating decreased ovarian reserve.

2. The application according to claim 1, characterized in that, The ingredients for preparing the Jin Kui Wen Jing Tang are: Evodia rutaecarpa, Ophiopogon japonicus, Angelica sinensis, Paeonia lactiflora, Ligusticum chuanxiong, Panax ginseng, Cinnamomum cassia, Colla corii asini, Paeonia suffruticosa, Zingiber officinale, Glycyrrhiza uralensis, and Pinellia ternata.

3. The application according to claim 1, characterized in that, According to the weight proportions, the ingredients of Jin Kui Wen Jing Tang are: 8-10 parts Evodia rutaecarpa, 8-10 parts Ophiopogon japonicus, 5-7 parts Angelica sinensis, 5-7 parts Paeonia lactiflora, 5-7 parts Ligusticum chuanxiong, 5-7 parts Panax ginseng, 5-7 parts Cinnamomum cassia, 5-7 parts Colla corii asini, 5-7 parts Paeonia suffruticosa, 5-7 parts Zingiber officinale, 5-7 parts Glycyrrhiza uralensis, and 5-7 parts Pinellia ternata.

4. The application according to claim 1, characterized in that, According to the weight proportions, the ingredients of Jin Kui Wen Jing Tang are: 9 parts Evodia rutaecarpa, 9 parts Ophiopogon japonicus, 6 parts Angelica sinensis, 6 parts Paeonia lactiflora, 6 parts Ligusticum chuanxiong, 6 parts Panax ginseng, 6 parts Cinnamomum cassia, 6 parts Colla corii asini, 6 parts Paeonia suffruticosa, 6 parts Zingiber officinale, 6 parts Glycyrrhiza uralensis, and 6 parts Pinellia ternata.

5. The application according to claim 1, characterized in that, The preparation method of Jin Kui Wen Jing Tang includes the following steps: Step 1: Take the donkey-hide gelatin, crush it, add 3-5 times the weight of the donkey-hide gelatin with water, heat and melt it to obtain the pre-treated donkey-hide gelatin, set aside; Step 2: Mix Evodia rutaecarpa, Ophiopogon japonicus, Angelica sinensis, Paeonia lactiflora, Ligusticum chuanxiong, Panax ginseng, Cinnamomum cassia, Paeonia suffruticosa, Zingiber officinale, Glycyrrhiza uralensis, and Pinellia ternata to obtain the material. Add 5-50 times the weight of water to the material, decoct, filter, and obtain the medicinal liquid. Step 3: Add the processed donkey-hide gelatin to the medicinal liquid, mix, and obtain the Wenjing Decoction.

6. The application of Jin Kui Wen Jing Tang combined with fermented Chinese medicinal herbs in the preparation of drugs for treating decreased ovarian reserve, characterized in that... The fermented Chinese medicine was prepared by boiling and cooling Rehmannia glutinosa, Cuscuta chinensis, Morinda officinalis, Angelica sinensis, Astragalus membranaceus and Bupleurum chinense, followed by fermentation with Lactobacillus rhamnosus CICC 23119, sterilization and filtration.

7. The application according to claim 6, characterized in that, The ingredients of Jin Kui Wen Jing Tang are: Evodia rutaecarpa, Ophiopogon japonicus, Angelica sinensis, Paeonia lactiflora, Ligusticum chuanxiong, Panax ginseng, Cinnamomum cassia, Colla corii asini, Paeonia suffruticosa, Zingiber officinale, Glycyrrhiza uralensis, and Pinellia ternata.

8. The application according to claim 6, characterized in that, The ingredients of Jin Gui Wen Jing Tang are: 8-10 parts Evodia rutaecarpa, 8-10 parts Ophiopogon japonicus, 5-7 parts Angelica sinensis, 5-7 parts Paeonia lactiflora, 5-7 parts Ligusticum chuanxiong, 5-7 parts Panax ginseng, 5-7 parts Cinnamomum cassia, 5-7 parts Colla corii asini, 5-7 parts Paeonia suffruticosa, 5-7 parts Zingiber officinale, 5-7 parts Glycyrrhiza uralensis, and 5-7 parts Pinellia ternata.

9. The application according to claim 6, characterized in that, The raw materials for the fermented Chinese medicine are, by weight, 3-5 parts Rehmannia glutinosa, 2.5-4 parts Cuscuta chinensis, 1.5-3 parts Morinda officinalis, 1.5-3 parts Angelica sinensis, 1-2.5 parts Astragalus membranaceus, and 0.8-2 parts Bupleurum chinense.

Images